Intelgenx Technologies Corp (IGXT)
0.15
-0.01
(-8.48%)
USD |
OTCM |
Apr 24, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 26.20M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -13.54% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 25.21 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -1.216 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 93.93% |
Profile
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe. |
URL | https://www.intelgenx.com |
Investor Relations URL | http://www.intelgenx.com/investors/ |
HQ State/Province | Quebec |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 21, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe. |
URL | https://www.intelgenx.com |
Investor Relations URL | http://www.intelgenx.com/investors/ |
HQ State/Province | Quebec |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 21, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |